A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema

NCT02994771 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Secondary Lymphedema

Interventions

DRUG: Lymfactin® [1 x 10E10 vp]
DRUG: Lymfactin® [1 x 10E11 vp]

Sponsor

Herantis Pharma Plc.